DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen
Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) ...
Dec 11, 2015
0
0